These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21403972)

  • 21. Microfluidic cell culture systems for drug research.
    Wu MH; Huang SB; Lee GB
    Lab Chip; 2010 Apr; 10(8):939-56. PubMed ID: 20358102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exact and approximate solutions for the decades-old Michaelis-Menten equation: Progress-curve analysis through integrated rate equations.
    Goličnik M
    Biochem Mol Biol Educ; 2011; 39(2):117-25. PubMed ID: 21445903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of different prediction methods for determination of the efficiency and selectivity on neuron-based sensors.
    Prasad S; Tuncel E; Ozkan M
    Biosens Bioelectron; 2006 Jan; 21(7):1045-58. PubMed ID: 15913979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extrinsic noise passing through a Michaelis-Menten reaction: a universal response of a genetic switch.
    Ochab-Marcinek A
    J Theor Biol; 2010 Apr; 263(4):510-20. PubMed ID: 20045705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.
    Muller PY; Milton M; Lloyd P; Sims J; Brennan FR
    Curr Opin Biotechnol; 2009 Dec; 20(6):722-9. PubMed ID: 19896825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dose-response relationship: relevance for medical practice].
    Klinkhardt U; Harder S
    Med Klin (Munich); 2000 May; 95(1 Spec No):9-14. PubMed ID: 10851842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parsing the effects of binding, signaling, and trafficking on the mitogenic potencies of granulocyte colony-stimulating factor analogues.
    Sarkar CA; Lowenhaupt K; Wang PJ; Horan T; Lauffenburger DA
    Biotechnol Prog; 2003; 19(3):955-64. PubMed ID: 12790662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Robustness of choice of number of doses for maximum likelihood estimation of the ED(50) in bioassay.
    Huang Y
    Stat Med; 2002 Aug; 21(15):2215-23. PubMed ID: 12210634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Designs for dose-escalation trials with quantitative responses.
    Bailey RA
    Stat Med; 2009 Dec; 28(30):3721-38. PubMed ID: 19579226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Hill equation: a review of its capabilities in pharmacological modelling.
    Goutelle S; Maurin M; Rougier F; Barbaut X; Bourguignon L; Ducher M; Maire P
    Fundam Clin Pharmacol; 2008 Dec; 22(6):633-48. PubMed ID: 19049668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stochastic simulation of biological reactions, and its applications for studying actin polymerization.
    Ichikawa K; Suzuki T; Murata N
    Phys Biol; 2010 Nov; 7(4):046010. PubMed ID: 21119218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose addition and the isobole method as approaches for predicting the cumulative effect of non-interacting chemicals: a critical evaluation.
    Bosgra S; van Eijkeren JC; Slob W
    Crit Rev Toxicol; 2009; 39(5):418-26. PubMed ID: 19514914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Finding the maximum safe dose level for heteroscedastic data.
    Tamhane AC; Logan BR
    J Biopharm Stat; 2004 Nov; 14(4):843-56. PubMed ID: 15587967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An overview of computer algorithms for deconvolution-based assessment of in vivo neuroendocrine secretory events.
    Veldhuis JD; Johnson ML
    Biotechniques; 1990 Jun; 8(6):634-9. PubMed ID: 2192741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative metrics for bio-modeling algorithm selection.
    Kaddi C; Quo CF; Wang MD
    Annu Int Conf IEEE Eng Med Biol Soc; 2008; 2008():4613-6. PubMed ID: 19163744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations.
    Tallarida RJ; Raffa RB
    Pharmacol Ther; 2010 Aug; 127(2):165-74. PubMed ID: 20546783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.